Tranexamic acid in the control of spontaneous bleeding in severe haemophilia.
D000293:Adolescent; D000367:Age Factors; D000614:Aminocaproates / Q000627:therapeutic use; D000933:Antifibrinolytic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001777:Blood Coagulation; D002648:Child; D003509:Cyclohexanecarboxylic Acids / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005169:Factor VIII / Q000627:therapeutic use; D005500:Follow-Up Studies; D006467:Hemophilia A / Q000150:complications / Q000188:drug therapy*; D006470:Hemorrhage / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D008297:Male; D010714:Phosphatidylethanolamines; D013997:Time Factors
D000614:Aminocaproates; D000933:Antifibrinolytic Agents; D003509:Cyclohexanecarboxylic Acids; D010714:Phosphatidylethanolamines; D005169:Factor VIII